QQ客服 官方微博 反馈留言

	P21 (waf1/cip1) is required for non-small cell lung cancer sensitive to Gefitinib treatment
	Zhao, Yi-Fan; Wang, Chong-Ren; Wu, Yan-Ming; Ma, Sheng-Lin; Ji, Yuan; Lu, Yan-Jun
刊名	BIOMEDICINE & PHARMACOTHERAPY
	2011
卷号	65期号:3
关键词	NSCLC p21 CDKs Gefitinib Beta-elemene
ISSN号	0753-3322
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4919566
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Zhao, Yi-Fan,Wang, Chong-Ren,Wu, Yan-Ming,et al. P21 (waf1/cip1) is required for non-small cell lung cancer sensitive to Gefitinib treatment[J]. BIOMEDICINE & PHARMACOTHERAPY,2011,65(3).
APA	Zhao, Yi-Fan,Wang, Chong-Ren,Wu, Yan-Ming,Ma, Sheng-Lin,Ji, Yuan,&Lu, Yan-Jun.(2011).P21 (waf1/cip1) is required for non-small cell lung cancer sensitive to Gefitinib treatment.BIOMEDICINE & PHARMACOTHERAPY,65(3).
MLA	Zhao, Yi-Fan,et al."P21 (waf1/cip1) is required for non-small cell lung cancer sensitive to Gefitinib treatment".BIOMEDICINE & PHARMACOTHERAPY 65.3(2011).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。